Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.
Poussin K, Pilati C, Couchy G, Calderaro J, Bioulac-Sage P, Bacq Y, Paradis V, Leteurtre E, Sturm N, Ramos J, Guettier C, Bardier-Dupas A, Boulai A, Wendum D, Selves J, Izard T, Nault JC, Zucman-Rossi J.
Poussin K, et al. Among authors: paradis v.
Oncoimmunology. 2013 Dec 1;2(12):e27090. doi: 10.4161/onci.27090. Epub 2014 Jan 3.
Oncoimmunology. 2013.
PMID: 24501689
Free PMC article.